Introduction, disclosures

Introduction content: Cursory refresher and review of ATTR Epidemiology and etiology of ATTR: U.S. & world statistics, demographics, genetics ATTR symptomology and diagnosis Pathophysiology: Protein malformation precipitated by TTR destabilization Organ involvement and complications: cardiologic, neurologic, musculoskeletal Diagnostic tests Tissue biopsy Bone radiotracer scintigraphy Nerve conduction studies Autonomic function testing Serum studies Imaging Staging Differential diagnoses Underdiagnosis and barriers to diagnosis and strategies for addressing them

Treatment in patients with TRR amyloidosis Pharmacotherapy: Patisiran, inotersen, symptomatic management Drugs in development: ALN-TTRsc02. and AKCEA-TTR-LRx Management of cardiomyopathy and polyneuropathy: Roles of diflunisal, tafamidis, beta blockers, diuretics Emerging strategies and trends in recent years Promoting active patient involvement in the care plan Best practice: Putting it all together Patient case(s)

Summary, conclusions, and best practice recap

 

By the end of the session the participant will be able to:

• Describe the epidemiology of ATTR, including its subtypes.
• Compare and contrast invasive and non-invasive methods in the diagnosis of ATTR’s complications.
• Describe challenges in the management of ATTR, including under-diagnosis and challenges patients face in understanding the diagnosis and treatment of ATTR.
• Describe available and emerging therapies for ATTR and design an appropriate therapeutic plan including active patient involvement.

ACCME Activity #0

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty Disclosure: Robert Chilton, MD, Professor of Medicine, Associate Program Director for Interventional Cardiology, Director Catheterization Lab/Clinical Proteomics, University of Texas, has no relevant financial disclosures.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Commercial Support Disclosure: This program is supported by educational grants from Akcea Therapeutics

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural and Linguistic Competence

*Required to view Printable PDF Version